U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07285538) titled 'Stereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer' on Nov. 26.
Brief Summary: This is a prospective, interventional, monocentric, clinical study of Stereotactic Body Radiation Therapy (SBRT) for primary or secondary renal tumors, delivering from 25-26 Gy/1 fraction to 42-48 Gy/3-4 fractions or 40-50 Gy/5 fractions (standard prescriptions for the internationl guidelines, according to tumor size), using a robotic accelerator -CyberKnife(R) (Accuray, Sunnyvale, CA)-, with fiducial-tracking, to observe the acute and late toxicity reduction (as primary objectives), due to the maximum precision...